Filing Details
- Accession Number:
- 0001714899-21-000080
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-08-04 19:14:09
- Reporting Period:
- 2021-08-02
- Accepted Time:
- 2021-08-04 19:14:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1714899 | Denali Therapeutics Inc. | DNLI | Biological Products, (No Disgnostic Substances) (2836) | 463872213 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1724310 | J. Ryan Watts | C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-08-02 | 8,543 | $50.80 | 2,183,866 | No | 4 | S | Indirect | See footnote |
Common Stock | Disposition | 2021-08-02 | 9,790 | $51.94 | 2,174,076 | No | 4 | S | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 156,691 | Direct |
Footnotes
- The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $50.42 to $51.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $51.42 to $52.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- Includes 156,691 restricted stock units.